ProQR Therapeutics BV (PRQR) - Net Assets
Based on the latest financial reports, ProQR Therapeutics BV (PRQR) has net assets worth $57.07 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($124.35 Million) and total liabilities ($67.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ProQR Therapeutics BV (PRQR) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $57.07 Million |
| % of Total Assets | 45.9% |
| Annual Growth Rate | 76.18% |
| 5-Year Change | 28.0% |
| 10-Year Change | -1.38% |
| Growth Volatility | 81.74 |
ProQR Therapeutics BV - Net Assets Trend (2012–2024)
This chart illustrates how ProQR Therapeutics BV's net assets have evolved over time, based on quarterly financial data. Also explore PRQR total asset value for the complete picture of this company's asset base.
Annual Net Assets for ProQR Therapeutics BV (2012–2024)
The table below shows the annual net assets of ProQR Therapeutics BV from 2012 to 2024. For live valuation and market cap data, see ProQR Therapeutics BV market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $88.56 Million | +93.69% |
| 2023-12-31 | $45.72 Million | -31.43% |
| 2022-12-31 | $66.68 Million | -41.11% |
| 2021-12-31 | $113.23 Million | +63.66% |
| 2020-12-31 | $69.19 Million | -34.31% |
| 2019-12-31 | $105.33 Million | +13.64% |
| 2018-12-31 | $92.69 Million | +135.69% |
| 2017-12-31 | $39.33 Million | -25.99% |
| 2016-12-31 | $53.14 Million | -40.83% |
| 2015-12-31 | $89.80 Million | -17.92% |
| 2014-12-31 | $109.40 Million | +123025.84% |
| 2013-12-31 | $-89.00K | -189.90% |
| 2012-12-31 | $99.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to ProQR Therapeutics BV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 42674000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.31 Million | 4.86% |
| Other Comprehensive Income | $27.60 Million | 31.16% |
| Other Components | $483.81 Million | 546.31% |
| Total Equity | $88.56 Million | 100.00% |
ProQR Therapeutics BV Competitors by Market Cap
The table below lists competitors of ProQR Therapeutics BV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zueblin Immobilien Holding AG
SW:ZUBN
|
$153.85 Million |
|
OM Holdings Ltd
KLSE:5298
|
$153.91 Million |
|
ALM Equity AB Pfd.
ST:ALM-PREF
|
$153.91 Million |
|
Temapol Polimer Plastik ve Insaat Sanayi Ticaret AS
IS:TMPOL
|
$153.98 Million |
|
Asian Energy Services Limited
NSE:ASIANENE
|
$153.78 Million |
|
Wellcall Holdings Bhd
KLSE:7231
|
$153.77 Million |
|
Portman Ridge Finance Corp
NASDAQ:PTMN
|
$153.76 Million |
|
Avaco Co. Ltd
KQ:083930
|
$153.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ProQR Therapeutics BV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 45,721,463 to 88,560,000, a change of 42,838,537 (93.7%).
- Net loss of 27,763,000 reduced equity.
- New share issuances of 71,635,000 increased equity.
- Other comprehensive income decreased equity by 1,096,388.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-27.76 Million | -31.35% |
| Share Issuances | $71.64 Million | +80.89% |
| Other Comprehensive Income | $-1.10 Million | -1.24% |
| Other Changes | $62.92K | +0.07% |
| Total Change | $- | 93.69% |
Book Value vs Market Value Analysis
This analysis compares ProQR Therapeutics BV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.43x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 93.94x to 1.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.02 | $1.55 | x |
| 2013-12-31 | $0.00 | $1.55 | x |
| 2014-12-31 | $4.94 | $1.55 | x |
| 2015-12-31 | $3.85 | $1.55 | x |
| 2016-12-31 | $2.28 | $1.55 | x |
| 2017-12-31 | $1.55 | $1.55 | x |
| 2018-12-31 | $2.73 | $1.55 | x |
| 2019-12-31 | $2.58 | $1.55 | x |
| 2020-12-31 | $1.40 | $1.55 | x |
| 2021-12-31 | $1.77 | $1.55 | x |
| 2022-12-31 | $0.94 | $1.55 | x |
| 2023-12-31 | $0.56 | $1.55 | x |
| 2024-12-31 | $1.08 | $1.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ProQR Therapeutics BV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -31.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -146.86%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 1.90x
- Recent ROE (-31.35%) is above the historical average (-51.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -2033.13% | 0.04x | 0.00x | $-3.24 Million |
| 2014 | -11.08% | -3874.44% | 0.00x | 1.05x | $-23.07 Million |
| 2015 | -23.20% | -221.45% | 0.09x | 1.11x | $-29.81 Million |
| 2016 | -73.59% | -1713.54% | 0.03x | 1.23x | $-44.42 Million |
| 2017 | -110.86% | 0.00% | -0.03x | 1.35x | $-47.57 Million |
| 2018 | -39.71% | -746.69% | 0.04x | 1.19x | $-46.19 Million |
| 2019 | -53.59% | -2935.64% | 0.01x | 1.25x | $-67.33 Million |
| 2020 | -66.66% | -4525.27% | 0.01x | 1.73x | $-53.55 Million |
| 2021 | -53.36% | -4549.81% | 0.01x | 1.84x | $-72.12 Million |
| 2022 | -96.06% | -1792.54% | 0.02x | 2.55x | $-71.13 Million |
| 2023 | -61.50% | -431.67% | 0.04x | 3.33x | $-32.69 Million |
| 2024 | -31.35% | -146.86% | 0.11x | 1.90x | $-36.62 Million |
Industry Comparison
This section compares ProQR Therapeutics BV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ProQR Therapeutics BV (PRQR) | $57.07 Million | 0.00% | 1.18x | $153.80 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-sta… Read more